Investing at the frontier of human health
Jefferson Life Sciences partners with pioneering teams to advance breakthrough technologies that redefine medicine. With a unique blend of investment, operational, and scientific expertise, we help unlock innovations that improve lives and shape the future of care.
Approach
Championing transformational, high-quality companies
At Jefferson Life Sciences, we invest in early clinical-stage companies with exceptional teams advancing bold, differentiated science. We seek investments with a clear path to commercial viability and multiple opportunities for success that can be truly transformational for patients, and for therapies with the resilience to succeed across market shifts and technology paradigms.
About
Discipline makes us selective.
Deep resources make us exceptional partners.
Drive allows us to revolutionize therapeutics.
Jefferson Life Sciences, part of Jefferson River Capital, is an investment firm committed to advancing transformative innovations in medicine. As a family office, our capital is patient and flexible, free from fund cycles and the pressure to force an exit. By combining deep scientific, operational, and investing expertise, we help turn bold scientific ideas into meaningful therapeutic solutions that create real unequivocal value for patients and shareholders.
We actively partner with our companies, bringing strategic expertise, operational guidance, extensive domain knowledge, and access to a deep network, including leading pharma executives, exceptional operators, key opinion leaders, and co-investment partners.
Jefferson Life Sciences takes pride in our selectivity. We know that sometimes the most promising ideas do not conform to traditional investment return cycles. We form long-term partnerships and focus exclusively on the ideas we genuinely believe will one day change the therapeutic landscape.
Meet Our Team
Experienced. Insightful. Engaged.
Our Companies
Exceptional science, with the potential to drive meaningful impact.
Our Ecosystem
Portfolio News
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development and generate early clinical data for SLC15A4 inhibitor
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo H...
Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer
Accomplished rare disease and neuromuscular biotech executive joins as company a...
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
Financing led by new investor, Deep Track Capital with participation from Janus ...
Contact Us
We’d love to hear from you!